Truist lowered its price goal for Integra LifeSciences to $13, down from $15.

Oct 23, 2026, 7:01 PM ETOpinionRead the original at marketscreener.com

Bad for IART

Truist lowered its target after Integra LifeSciences' third-quarter results, signaling a weaker view of its shares. Keeping a Hold rating softens the message, but does not erase the target cut.

IART · Integra LifeSciences Holdings Corporation

AI read · Bad for IART

The AI's read

This is an analyst's view of Integra's shares, not a new company result. The lower target suggests Truist sees less room for the share price to rise than before. Its unchanged Hold rating softens that signal, but the target cut remains the main new information.

Get alerts for IART

Follow Integra LifeSciences Holdings Corporation (IART) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for IART

Free on the App Store and Google Play, or on the web.